Welcome to our dedicated page for Ironwood SEC filings (Ticker: IRWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ironwood Pharmaceuticals, Inc. filings document a Nasdaq-listed biotechnology company focused on gastrointestinal and rare disease therapies. Its Form 8-K reports include operating and financial results, business updates for LINZESS and apraglutide, regulatory and pricing matters involving LINZESS, and financing-related disclosures tied to credit agreements and liquidity conditions.
Proxy filings cover board elections, executive compensation votes, equity incentive plan matters, auditor ratification, and annual meeting procedures. Other filings address governance changes, Nasdaq listing-compliance matters for its Class A common stock, and the registered security structure of IRWD shares on the Nasdaq Global Select Market.
Ironwood Pharmaceuticals reported proposed sales of Class A common stock via a Form 144 tied to restricted stock unit awards, including awards of 62,218 (03/08/2022), 80,198 (03/08/2023), 88,292 (03/05/2024) and 180,000 (05/20/2025) shares.
Each listed award was granted under the Issuer's 2019 Equity Incentive Plan or its amended and restated 2019 Equity Incentive Plan. The filing lists the securities and grant dates associated with the proposed sales.
Ironwood Pharmaceuticals reports a 9.85% beneficial stake held by Armistice Capital and Steven Boyd. The filing shows 16,025,000 shares of Class A common stock as beneficially owned as of 12/31/2025, with 16,025,000 shares of shared voting power and shared dispositive power.
The statement filed jointly and signed 02/17/2026 attributes ownership to Armistice Capital as investment manager of Armistice Capital Master Fund Ltd.; the Master Fund is identified as the direct holder.
Ironwood Pharmaceuticals officer Ronald Silver reported a planned stock sale. On January 5, 2026, he sold 35,416 shares of Ironwood Class A Common Stock at $4.60 per share in a transaction coded as a sale. The filing states this sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by Silver, which is designed to allow insiders to sell shares according to a set schedule. After this transaction, he beneficially owned 276,809 shares of Ironwood stock, held directly. A footnote explains that the 35,416 shares sold had been acquired under Ironwood’s employee stock purchase plan on December 31, 2025.
Ironwood Pharmaceuticals insider activity: A reporting person associated with Ironwood Pharmaceuticals received an award of 4,178 shares of Class A common stock on 12/15/2025 at a price of $0 per share. The filing states this grant was issued under the company’s Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.
After this transaction, the reporting person directly beneficially owns 251,858 Class A shares and indirectly beneficially owns 15,919,435 Class A shares through Sarissa Capital Management LP and related funds, reflecting both personal and fund-related positions in IRONWOOD PHARMACEUTICALS INC (IRWD).
Ironwood Pharmaceuticals reported that the U.S. Department of Health and Human Services has set the Medicare “Maximum Fair Price” for LINZESS (linaclotide) at $136 for a 30-day equivalent supply. This Maximum Fair Price will become the new Medicare net price starting January 1, 2027 under the Inflation Reduction Act of 2022.
The company states that this revised price for LINZESS is in line with its expectations, indicating the decision aligns with its planning around the product’s U.S. Medicare pricing.
Ironwood Pharmaceuticals Inc. (IRWD) reported an insider transaction by its Chief Commercial Officer. On 11/17/2025, the officer sold 6,016 shares of Class A common stock at $3.32 per share. According to the disclosure, this sale was made automatically to cover tax withholding obligations arising from the vesting of restricted stock units and was not a discretionary trade. After this transaction, the officer beneficially owned 235,264 shares of Ironwood common stock.
Ironwood Pharmaceuticals (IRWD) furnished an Item 2.02 Form 8-K announcing a press release with an update on recent business activities and results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and incorporated by reference. The information is furnished, not filed, under the Exchange Act.
Ironwood Pharmaceuticals (IRWD) reported stronger Q3 2025 results. Total revenues were $122.1 million, up from $91.6 million a year ago, driven mainly by collaborative revenue from the LINZESS partnership with AbbVie in North America ($120.5 million). Operating income rose to $75.5 million from $25.6 million, and net income improved to $40.1 million versus $3.6 million, with diluted EPS of $0.23.
Expenses declined year over year, with research and development at $22.5 million and selling, general and administrative at $21.9 million; restructuring expense was $2.2 million. Cash and cash equivalents increased to $140.4 million, supported by $52.5 million net cash from operating activities for the nine-month period. The company reported a current portion of convertible senior notes of $199.5 million and $385.0 million outstanding on its revolving credit facility. As of October 31, 2025, 162,678,647 Class A shares were outstanding.
For the first nine months of 2025, revenues were $248.4 million and net income was $26.3 million, reflecting improved profitability compared to the prior-year period.
Ironwood Pharmaceuticals, Inc. reported that Andrew Dreyfus has notified the company of his resignation from its Board of Directors. His resignation is effective November 1, 2025.
The company explains that Mr. Dreyfus is stepping down because he has been appointed President and Chief Executive Officer of the National Institute for Health Care Management (NIHCM) Foundation. It states that his decision to resign is not due to any disagreement with Ironwood regarding its operations, policies, or practices.
Ironwood expresses appreciation for Mr. Dreyfus’s service and notes his contributions during his tenure on the Board of Directors.
Alexander J. Denner, a director and 10% owner of Ironwood Pharmaceuticals (IRWD), reported a non-derivative acquisition of 11,718 shares of Class A common stock on 09/15/2025 at no cash price under the company's non-employee director compensation policy effective January 1, 2024. After the reported transaction, Mr. Denner directly beneficially owned 247,680 shares. The filing also reports that his indirect beneficial ownership held through Sarissa Capital and related funds totals 15,919,435 shares, a decrease attributed to termination of an investment advisory agreement for a separately managed account. The report is signed 09/17/2025.
Alexander J. Denner, a director and 10% owner of Ironwood Pharmaceuticals (IRWD), reported a non-derivative acquisition of 11,718 shares of Class A common stock on 09/15/2025 at no cash price under the company's non-employee director compensation policy effective January 1, 2024. After the reported transaction, Mr. Denner directly beneficially owned 247,680 shares. The filing also reports that his indirect beneficial ownership held through Sarissa Capital and related funds totals 15,919,435 shares, a decrease attributed to termination of an investment advisory agreement for a separately managed account. The report is signed 09/17/2025.